Pain, Inflammation, and Dermatology Lecture Review

0.0(0)
Studied by 0 people
call kaiCall Kai
Locked
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/37

flashcard set

Earn XP

Description and Tags

Vocabulary-style flashcards based on the Pain, Inflammation, and Dermatology lecture notes covering analgesics, opioids, migraine treatments, acne, and topical steroids.

Last updated 2:28 AM on 8/8/26
Name
Mastery
Learn
Test
Matching
Spaced
Call with Kai
Chat

No analytics yet

Send a link to your students to track their progress

38 Terms

1
New cards

Nocioceptive Pain

Pain due to inflammation or acute damage; most effectively managed with NSAIDs, injections, surgery, and possibly short-term opioids.

2
New cards

Centralized Pain

Pain that is often widespread and associated with fatigue and mood disturbances; treated with CNS-acting drugs and non-pharmacologic therapy such as exercise.

3
New cards

Peripheral Pain

Pain described as a pins and needles sensation following nerve distribution; managed with local treatments (topical, surgery, injection) or CNS-acting drugs.

4
New cards

Acetaminophen

A simple analgesic with anti-pyretic effects but no anti-inflammatory effect; unlike NSAIDs, it is not associated with increased risk for bleeding or renal dysfunction.

5
New cards

Acetaminophen Max Daily Dose

The standard maximum for an adult is 4grams4\,grams, though some suggest 3grams3\,grams; a lower dose of 2grams2\,grams is recommended for those at risk for hepatotoxicity (e.g., alcohol use disorder).

6
New cards

COX-1 Enzyme

A ‐house-keeping‑ enzyme responsible for maintaining GI mucosa, hemostatic integrity, and renal hemodynamics.

7
New cards

COX-2 Enzyme

The primary target of NSAIDs responsible for triggering pain and inflammation in the body.

8
New cards

NSAID COX-2 Selectivity Ranking

Ordered from most to least selective: CELECOXIB > MELOXICAM > IBUPROFEN > NAPROXEN.

9
New cards

Valdecoxib

Removed from the market in 2005 due to concerns regarding an increased risk for cardiovascular events like myocardial infarction.

10
New cards

Ketorolac

An NSAID that must not be used for more than 5 consecutive days due to an increased risk of gastrointestinal bleeding.

11
New cards

Diclofenac

The only NSAID available as a topical formulation (topical gel and patch).

12
New cards

Hydrocortisone

A short-acting systemic corticosteroid with a mineralcorticoid activity rating of ++.

13
New cards

Dexamethasone

A long-acting systemic corticosteroid with 0 mineralcorticoid activity.

14
New cards

HPA Axis Suppression

The risk that the body stops producing cortisol after taking systemic corticosteroids (5mg\ge 5\,mg daily of prednisone equivalent) for 21 days or longer.

15
New cards

Adrenal Crisis

A condition caused by the abrupt discontinuation of systemic steroids following HPA axis suppression; symptoms include abdominal pain, hypotension, and dehydration.

16
New cards

Morphine

A naturally occurring full mu-agonist opioid.

17
New cards

Tramadol

A weak mu-agonist opioid known to increase serotonin and norepinephrine.

18
New cards

Fentanyl Patch

A synthetic opioid that should only be initiated in patients taking at least 60mg60\,mg of morphine or equivalent per day.

19
New cards

Kappa Receptor Clinical Effects

Analgesia and dysphoria.

20
New cards

Hydrocodone-to-Oxycodone Conversion

A total daily dose of 40mg40\,mg hydrocodone is equivalent to 26.67mg26.67\,mg of oral oxycodone per day.

21
New cards

Naloxone

A medication that reverses the effect of opioids, primarily if opioids slow down breathing; it cannot be given orally due to poor oral bioavailability and slow onset.

22
New cards

Hydrocodone Metabolites

Norhydrocodone and hydromorphone (found in urine drug tests).

23
New cards

Naltrexone

An opioid antagonist that blocks the effects of opioids; usually administered as a once-monthly intramuscular injection for opioid use disorder.

24
New cards

Methadone

A full opioid agonist at the mu receptor with a long duration of action used for opioid use disorder to provide relief from cravings; must be administered via an opioid treatment program.

25
New cards

Neuropathic Pain Neurotransmitters

Norepinephrine and GABA.

26
New cards

Gabapentin Clinically Effective Dose

Generally considered to be 1800mg/day1800\,mg/day, as lower or higher doses may lack benefit or increase adverse effects.

27
New cards

Lidocaine 5% Patch

A topical treatment only FDA approved for postherpetic neuralgia.

28
New cards

Fibromyalgia First-Line Treatment

Tricyclic antidepressants (e.g., amitriptyline), which should be dosed at bedtime to target symptoms and minimize daytime drowsiness.

29
New cards

Milnacipran

A serotonin-norepinephrine reuptake inhibitor (SNRI) that is only indicated for fibromyalgia.

30
New cards

Triptans

Serotonin agonists at intracranial blood vessels and sensory nerves that cause vasoconstriction to reduce migraine pain and inflammation.

31
New cards

Frovatriptan

The longest-acting triptan medication.

32
New cards

CGRP Antagonists

Neuropeptide blockers used for migraines; examples include Ubrelvy (acute), Aimovig (prophylaxis), and Nurtec (both).

33
New cards

Retinoids

Vitamin A derivatives that enhance skin cell turnover; should be avoided in pregnancy due to severe risk of teratogenicity.

34
New cards

Isotretinoin Monitoring

Requires the documentation of two forms of birth control, monthly pregnancy tests for females, and periodic lipid and liver function tests.

35
New cards

Propionibacterium acnes

The bacteria most commonly associated with acne.

36
New cards

Topical Potency by Site

High (Soles/Palms), Intermediate (Trunk/Legs/Arms), and Low (Face/Armpits/Genitals).

37
New cards

Topical Steroid Potency Ranking

Most to least potent: Clobetasol propionate = Augmented betamethasone dipropionate > Triamcinolone acetonide > Hydrocortisone.

38
New cards

Topical Absorption Factors

Factors increasing absorption include heat, hydrated skin, application to denuded or intertriginous areas, occlusive dressings, and increased body surface area to body weight ratio.